Bp Plc decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 12.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,000 shares of the life sciences company’s stock after selling 2,300 shares during the quarter. Bp Plc’s holdings in Illumina were worth $4,800,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc raised its holdings in Illumina by 1.8% in the third quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after purchasing an additional 188,516 shares in the last quarter. Oregon Public Employees Retirement Fund raised its holdings in Illumina by 66,581.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after purchasing an additional 10,546,495 shares in the last quarter. Jennison Associates LLC raised its holdings in Illumina by 12.3% in the third quarter. Jennison Associates LLC now owns 4,826,216 shares of the life sciences company’s stock worth $1,771,511,000 after purchasing an additional 528,635 shares in the last quarter. Capital International Investors bought a new position in Illumina in the third quarter worth $1,482,837,000. Finally, Jackson Square Partners LLC raised its holdings in Illumina by 7.7% in the third quarter. Jackson Square Partners LLC now owns 1,429,221 shares of the life sciences company’s stock worth $524,609,000 after purchasing an additional 102,639 shares in the last quarter. 96.10% of the stock is owned by institutional investors.
In other Illumina news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction dated Wednesday, December 26th. The stock was sold at an average price of $273.87, for a total value of $903,771.00. Following the transaction, the director now directly owns 339,879 shares of the company’s stock, valued at $93,082,661.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Omead Ostadan sold 644 shares of the firm’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $306.74, for a total value of $197,540.56. Following the completion of the transaction, the executive vice president now directly owns 22,257 shares in the company, valued at $6,827,112.18. The disclosure for this sale can be found here. Insiders sold 35,947 shares of company stock worth $11,026,616 over the last three months. Insiders own 0.54% of the company’s stock.
Shares of NASDAQ:ILMN opened at $293.52 on Thursday. Illumina, Inc. has a 1-year low of $216.34 and a 1-year high of $372.61. The firm has a market cap of $43.44 billion, a PE ratio of 51.31, a P/E/G ratio of 2.03 and a beta of 1.20. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 0.23.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, January 29th. The life sciences company reported $1.32 EPS for the quarter, missing the consensus estimate of $1.36 by ($0.04). The business had revenue of $867.00 million during the quarter, compared to the consensus estimate of $865.33 million. Illumina had a return on equity of 24.51% and a net margin of 24.79%. Illumina’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.44 earnings per share. On average, sell-side analysts predict that Illumina, Inc. will post 6.51 EPS for the current fiscal year.
A number of equities analysts have issued reports on the company. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, October 24th. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $340.00 to $370.00 in a report on Thursday, January 3rd. Barclays increased their price objective on Illumina from $350.00 to $370.00 and gave the stock an “overweight” rating in a report on Wednesday, October 24th. Finally, Leerink Swann upgraded Illumina to an “outperform” rating and reduced their price target for the company from $380.00 to $365.00 in a report on Wednesday, January 30th. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Illumina presently has an average rating of “Buy” and an average target price of $346.40.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Story: Correction
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.